服务热线
15339069646服务热线
15339069646| Item | Cat. No. | Type | Clone No |
| Anti-DKK1 mAbs [Sirexatamab Biosimilar] (MABL-5235) | MABL-5235 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-SLITRK6 mAbs [Sirtratumab Biosimilar] (MABL-5236) | MABL-5236 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-IL6 mAbs [Sirukumab Biosimilar] (MABL-5237) | MABL-5237 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDL1/CD274 mAbs [Socazolimab Biosimilar] (MABL-5238) | MABL-5238 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-CD40LG/CD154 mAbs [Ruplizumab Biosimilar] (MABL-5198) | MABL-5198 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-CFB/BFD mAbs [Ruxoprubart Biosimilar] (MABL-5199) | MABL-5199 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-ERBB3/HER3 mAbs [Ruzaltatug Biosimilar] (MABL-5200) | MABL-5200 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL13;IL4 mAbs [Romilkimab Biosimilar] (MABL-5185) | MABL-5185 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-SARS-CoV-2 Spike RBD mAbs [Romlusevimab Biosimilar] (MABL-5186) | MABL-5186 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-SOST mAbs [Romosozumab Biosimilar] (MABL-5187) | MABL-5187 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-IFNA1 mAbs [Rontalizumab Biosimilar] (MABL-5188) | MABL-5188 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-RSPO3 mAbs [Rosmantuzumab Biosimilar] (MABL-5189) | MABL-5189 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Rosnilimab Biosimilar] (MABL-5190) | MABL-5190 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-FOLH1/GCPII/PSMA mAbs [Rosopatamab Biosimilar] (MABL-5191) | MABL-5191 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-DLL3 mAbs [Rovalpituzumab Biosimilar] (MABL-5192) | MABL-5192 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-ITGAL/CD11A/LFA1A and ITGB2/CD18 mAbs [Rovelizumab Biosimilar] (MABL-5193) | MABL-5193 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-FCGRT/FcRn mAbs [Rozanolixizumab Biosimilar] (MABL-5194) | MABL-5194 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-ICOS/CD278 mAbs [Rozibafusp Biosimilar] (MABL-5195) | MABL-5195 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-PDCD1/CD279/PD1 mAbs [Rulonilimab Biosimilar] (MABL-5196) | MABL-5196 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-ERBB2/CD340/HER2;CD3E mAbs [Runimotamab Biosimilar] (MABL-5197) | MABL-5197 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿（Mabioway）生物科技有限公司 版权所有
地址：陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话：15339069646 邮箱：info@mabioway.cn